Chemunex, a French biotech company, has become the latest in a series of companies to defect from Nasdaq Europe in favour of a sole listing on its home market.

Chemunex, one of the first stocks to list on what was then Easdaq in November 1997, has asked Nasdaq Europe to delist its shares with effect from November 23. Chemunex already has a secondary listing on Euronext, which it launched in 1998. This will become its sole listing in the future.